Aptose Biosciences Inc. (APS) 2016年年度报告「TSX」.pdf

1、 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549 FORM 20-F(Mark One)Registration statement pursuant to Section 12(b)or 12(g)of the Securities Exchange Act of 1934.Or Annual report pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934.Or Annual report pursuant to S

2、ection 13 or 15(d)of the Securities Exchange Act of 1934.Or Shell company report pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934.Date of event requiring this shell company report _.Commission file number 001-32001 APTOSE BIOSCIENCES INC.(Exact Name of Registrant as Specified in

3、 Its Charter)Canada(Jurisdiction of Incorporation or Organization)5955 Airport Road,Suite#228Mississauga,OntarioL4V 1R9Canada(Address of Principal Executive Offices)Gregory ChowChief Financial Officer5955 Airport Road,Suite#228Mississauga,OntarioL4V 1R9CanadaTelephone:(647)479-9828Facsimile:(905)234

4、-2120(Name,Telephone,E-mail and/or Facsimile number and Address of Company Contact Person)Securities registered or to be registered pursuant to Section 12(b)of the Act:None Title of Each Class Name of Each Exchange On Which RegisteredCommon Shares NASDAQ Stock Market Securities registered or to be r

5、egistered pursuant to Section 12(g)of the Act:None Securities for which there is a reporting obligation pursuant to Section 15(d)of the Act:None Indicate the number of outstanding shares of each of the issuers classes of capital or common stock as of the close of the period covered by the annual rep

6、ort.Common Shares,without par value,at December 31,2016:15,721,388 Indicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes No If this is an annual or transition report,indicate by check mark if the registrant is not required to file r